Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24783932 | 0.81 | UCHL1 (0.50) | UCHL1JAK1ROCK2ROCK1CDC42BPB | |
| SCHEMBL25124401 | 0.71 | ROCK2 (0.41) | JAK1ROCK2ROCK1CDC42BPBAKT1 | |
| SCHEMBL24783742 | 0.67 | CLK2 (0.42) | ROCK2AKT1AKT2 | |
| SCHEMBL25124543 | 0.64 | CYP17A1 (0.40) | UCHL1JAK1ROCK2ROCK1CDC42BPB | |
| SCHEMBL30457290 | 0.61 | ROCK2 (0.34) | CCNCCDK8ROCK2ROCK1AKT1 | |
| SCHEMBL17864434 | 0.60 | PIM1 (0.39) | ROCK2AKT1AKT2LRRK2BRD4 | |
| SCHEMBL24783739 | 0.60 | S1PR1 (0.43) | UCHL1LRRK2EZH2 | |
| SCHEMBL3740850 | 0.60 | AKT2 (0.70) | ROCK2AKT1AKT2ACVR1 | |
| SCHEMBL8026865 | 0.59 | QDPR (0.51) | — | |
| SCHEMBL21233196 | 0.59 | CYP11B2 (0.47) | ROCK2ROCK1CDC42BPBAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | UCHL1 1759/4885JAK1 4857/4885CCNC 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.